Darbepoetin alfa treatment of anemia secondary to chronic renal failure in dialysis patients: results of a French multicenter study;Traitement par la darbepoetin alfa de l'anémie liée à l'insuffisance rénale chronique chez les patients dialysés : résultats d'une étude multicentrique française

Nephrologie et Therapeutique

Volumn 2, Issue 4, 2006, Pages 191-199

  Kessler, Michèle ^a   Hannedouche, Thierry ^b   Fitte, Henry ^c   Cayotte, Jean Louis ^d   Urena, Pablo ^e   Réglier, Jean Christophe ^f  

^a CHU NANCY BRABOIS   (France)

^b HÔPITAL CIVIL   (France)

^c Centre d'hémodialyse privé de Monaco   (France)

^d polyclinique Saint Martin   (France)

^e clinique de l'Orangerie   (France)

^f Amgen SA   (France)

Author keywords

Chronic renal failure; Darbepoetin alfa; Dialysis; Recombinant human erythropoietin; renal anemia

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; DRUG DERIVATIVE; ERYTHROPOIETIN; HEMOGLOBIN;

ANEMIA; ARTICLE; BRONCHITIS; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DIALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; FEMALE; FRANCE; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERITONEAL DIALYSIS; THROMBOSIS; AGED; INTRAVENOUS DRUG ADMINISTRATION; RENAL REPLACEMENT THERAPY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

AGED; ANEMIA; ERYTHROPOIETIN; FEMALE; FRANCE; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; KIDNEY FAILURE, CHRONIC; MALE; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 33748500406     PISSN: 17697255     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nephro.2006.06.004     Document Type: Article

References (22)

1. Eschbach J.W. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int. 35 (1989) 134-148
2. Sundal E., and Kaeser U. Correction of anaemia of chronic renal failure with recombinant human erythropoietin: safety and efficacy of one year's treatment in a European multicentre study of 150 haemodialysis-dependent patients. Nephrol. Dial. Transplant. 4 (1989) 979-987
3. Evans R.W., Rader B., and Manninen D.L. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA 263 (1990) 825-830
4. Moreno F., Sanz-Guajardo D., Lopez-Gomez J.M., Jofre R., and Valderrabano F. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. J. Am. Soc. Nephrol. 11 (2000) 335-342
5. Revicki D.A., Brown R.E., Feeny D.H., Henry D., Teehan B.P., Rudnick M.R., et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am. J. Kidney Dis. 25 (1995) 548-554
6. Halstenson C.E., Macres M., Katz S.A., Schnieders J.R., Watanabe M., Sobota J.T., et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin. Pharmacol. Ther. 50 (1991) 702-712
7. Macdougall I.C., Gray S.J., Elston O., Breen C., Jenkins B., Browne J., et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J. Am. Soc. Nephrol. 10 (1999) 2392-2395
8. Revised European best practice guidelines for the management of anaemia in patients with chronique renal failure. Nephrol. Dial. Transplant. 19 Suppl 2 (2004) (ii1-47)
9. Kaufman J.S., Reda D.J., Fye C.L., Goldfarb D.S., Henderson W.G., Kleinman J.G., et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N. Engl. J. Med. 339 (1998) 578-583
10. Lai P.H., Everett R., Wang F.F., Arakawa T., and Goldwasser E. Structural characterization of human erythropoietin. J. Biol. Chem. 261 (1986) 3116-3121
11. Egrie J.C., Grant J.R., Gillies D.K., Aoki K.H., and Strickland T.W. The role of carbohydrate on the biological activity of erythropoietin. Glycoconjugate J. 10 (1993) 263
12. Egrie J.C., and Browne J.K. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol. Dial. Transplant. 16 Suppl. 3 (2001) 3-13
13. Singlas E. Pharmacologie clinique de la darbepoetin alfa, une nouvelle protéine stimulant l'érythropoïèse (NESP). Lett. Pharmacol. 17 (2003) 1-8
14. Locatelli F., Canaud B., Giacardy F., Martin-Malo A., Baker N., and Wilson J. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEPO). Nephrol. Dial. Transplant. 18 (2003) 362-369
15. Vanrenterghem Y., Barany P., Mann J.F.E., Kerr P.G., Wilson J., Baker N.F., et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int. 62 (2002) 2167-2175
16. Martinez Castelao A., Reyes A., Valdés F., Otero A., Lopez de Novales E., Pallardo L., et al. Estudio multicéntrico de darbepoetin alfa en el tratamiento de la anemia secondarité a insuficienca renal cronica en dialisis. Nefrologia 23 (2003) 114-124
17. Brunkhorst R., Bommer J., Braun J., Haag-Weber M., Gill C., and Wagner T. Darbepoetin alfa effectively maintains haemoglobin concentrations at extented dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients. Nephrol. Dial. Transplant. 19 (2004) 1224-1230
18. Bristoyiannis G., Germanos N., Grekas D., Hatzidimitriou C., Iatrou C., Memmos D., et al. Unit dosing of darbepoetin alfa for the treatment of anemia in patients with end-stage renal disease being switched from recombinant human erythropoietin: result of a phase IIIb, 27-week, multicenter, open-label study in Geek patients. Curr. Ther. Res. 66 (2005) 195-211
19. Aljama P., Bommer J., Canaud B., Carrera F., Eckardt K.-U., Hörl W.H., et al. Practical guidelines for the use of NESP in treating renal anaemia. Nephrol. Dial. Transplant. 16 Suppl 3 (2001) 23-28
20. Nissenson A.R., Swan S.K., Lindberg J.S., Soroka S.D., Beatey R., Wang C., et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am. J. Kidney Dis. 40 (2002) 110-118
21. Cervelli M.J., Gray N., McDonald S., Gentgall M.G., and Disney A.P.S. Randomized cross-over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients. Nephrol. 10 (2005) 129-135
22. Aarup M., Bryndum J., Dieperink H., and Joffre P. Clinical implications of converting stabile haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa. Nephrol. Dial. Transplant. 21 (2006) 1312-1316